Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510(k) clearance from the FDA. The system is designed to ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Continuous glucose monitor maker Dexcom announced that it will partner with insulin pump maker Silicon Valley-based Asante Solutions so that users of Asante devices will be able to access that data ...

Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s. The company ...

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...

DexcomDXCM stock fell Thursday after the diabetes devices maker's second-quarter earnings and revenue topped estimates and the company named a new chief executive officer. The company raised full-year ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...